Immunex Corporation

Csl Limited

Csl Behring Lengnau Ag

Innunex Corporation

Eugene Maraskovsky

Dirk M Anderson

Laurent J Galibert

William C Dougall

Brent Steven McKenzie

Andrew Donald Nash

Hilary Jean McKenna

Gino Luigi Vairo

Nick Wilson

Samantha Busfield

Peter Frederick Curwen

Thomas Weimer

Con Panousis

Charles R Maliszewski

David Haskett Lynch

Sabine Pestel

Kenneth Allan Brasel

Luis G Borges

Anne Verhagen

Marco Hofmann

Huy Huynh

Debra Pauline Drane

Jefferey Stephen Boyle

Brent Steven Mckenzie

Deborah Pauline Drane

The present invention relates to a recombinant polypeptide comprising a truncated von Willebrand Factor (VWF) capable of binding to blood coagulation Factor VIII (FVIII) for use in reducing the immunogenicity of Factor VIII (FVIII) wherein said recombinant polypeptide and a blood coagulation Factor VIII (FVIII) protein are co-administered to a subject suffering from a 10 blood coagulation disorder. The invention further relates to pharmaceutical compositions and kits for said use.

Modulation of FVIII immunogenicity by truncated VWF

The present disclosure provides a method for treating lupus, Sj&#xf6;rgen's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor &#x3b1; (IL-3R&#x3b1;) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p DCs) and basophils to which it binds.

Compositions and methods for targeting type 1 interferon producing cells

The present invention is directed to a method for treating an inflammatory neurodegenerative condition of the CNS in a subject comprising administering to said subject a G-CSF or G-CSFR inhibiting agent selected from the group consisting of an antibody specific for G-CSF or G-CSFR, a soluble G-CSFR or a G-CSF-binding portion thereof and a 20 to 30 nucleotide sense or antisense molecule targeted to a nucleic acid molecule encoding G-CSF.

Treatment of neurological conditions

The present invention is directed to a method for treating an inflammatory neurodegenerative condition of the CNS in a subject comprising administering to said subject a G-CSF or G-CSFR inhibiting agent selected from the group consisting of an antibody specific for G-CSF, a soluble G-CSFR or a G-CSF-binding portion thereof and a 20 to 30 nucleotide sense or antisense molecule targeted to a nucleic acid molecule encoding G-CSF.

A method for treating or preventing an inflammatory bowel disease (IBD) in a subject, the method comprising administering to the subject a compound that inhibits granulocyte-macrophage colony stimulating factor (GM-CSF) signaling.

Method of treating inflammatory bowel disease

A method for the treatment of a condition which is characterized by CD 123-expressing cells in a patient comprises administering to the patient (i) an antibody or antibody fragment which binds selectively to IL-3R&#x3b1;(CD 123), and (ii) an immunostimulating complex which comprises saponin, a sterol and a phospholipid.

Immunotherapeutic method involving CD123 (IL-3R&#x3b1;) antibodies and immunostimulating complex

Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.

Receptor activator of NF-kappaB

Methods of treating lupus by administering humanized anti-interleukin 3 receptor alpha chain antibodies

Flt3-ligand can be used to generate large numbers of dendritic cells from hematopoietic progenitor and stem cells. Flt3-ligand can be used to augment immune responses in vivo, and expand dendritic cells ex vivo. Such dendritic cells can then be used to present tumor, viral or other antigens to naive T cells, can be useful as vaccine adjuvants. When flt3-L is used and/or administered in combination with other reactive agents, e.g. CD40 binding proteins and 4-1BBL or antibodies reactive with 4-1BB, the combination further enhances immune responses and the effectiveness of vaccine adjuvants.

Methods of preparing dendritic cells with flt3-ligand and antigen

Isolated ligands, DNAs encoding such ligands, and pharmaceutical compositions made therefrom, are disclosed. The isolated ligands can be used to enhance the functional capacity of dendritic cells.

Method for enhancing the functional capacity of dendritic cells

Receptor activator of NF-&kgr;B

Antigen-expressing, activated dendritic cells are disclosed. Such dendritic cells are used to present tumor, viral or bacterial antigens to T cells, and can be useful in vaccination protocols. Other cytokines can be used in separate, sequential or simultaneous combination with the activated, antigen-pulsed dendritic cells. Also disclosed are methods for stimulating an immune response using the antigen-expressing, activated dendritic cells.

Method of stimulating an immune response with activated dendritic cells

Receptor activator of NF-.kappa.B

Growing community of inventors

Kew, Australia

Eugene Maraskovsky